Tech Company Financing Transactions
Osivax Funding Round
Osivax secured a $10 million Series B funding round on 3/4/2025. Investors included Meiji.
Transaction Overview
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
?70 Rue Saint Jean Dieu
Lyon, 69007
France
Lyon, 69007
France
Phone
Website
Email Address
Overview
Osivax is a clinical-stage biotechnology company developing a transformative pipeline of universal vaccines uniquely designed to leverage both arms of the immune system: superior T-cell immune responses generated by its proprietary oligoDOM® technology, and B-cell responses brought by conventional vaccines. Osivax' mission is to develop universal vaccine candidates designed to provide protection against viruses that mutate rapidly, starting with influenza and rapidly expanding to other areas such as sarbecovirus.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Alexandre Le Vert
Chief Medical Officer
Nicola Groth
Chief Technical Officer
Vincent Bille
VP - Bus. Development
Delphine Guyon-Gellin
VP - Bus. Development
Florence Nicolas
VP - Finance
Florian Sourd
VP - Regulatory Affairs
Linda Lebon
Browse more venture capital transactions:
Prev: 3/4/2025: Mews venture capital transaction
Next: 3/4/2025: Garuda Therapeutics venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to document every notable VC transaction. VC transactions reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs